Regis Healthcare Ltd. (AU:REG)
ASX:REG
Top Page
Regis Healthcare Ltd.
(Sydney:REG)
Select Model
Select Model
Rating:56Neutral
Price Target:
AU$6.50
▲(7.97% Upside)
Action:ReiteratedDate:11/28/25
Regis Healthcare Ltd. demonstrates positive technical momentum and operational efficiency, contributing to a moderate overall score. However, financial risks due to high leverage and a high P/E ratio indicating potential overvaluation are significant concerns. The lack of earnings call data and corporate events limits further insights.
Positive Factors
Stable Revenue Base
Regis’ revenue is anchored in government funding and resident contributions, creating a predictable cash-flow foundation. That structural funding linkage and the essential nature of aged-care services support occupancy-driven revenues and downside protection versus discretionary industries.
Negative Factors
High Financial Leverage
Negative equity and an unfavorable debt-to-equity profile signal heavy reliance on debt financing. High leverage constrains strategic flexibility, raises refinancing and interest-rate sensitivity, and increases the risk that operational shocks translate into balance-sheet stress.
Read all positive and negative factors
Positive Factors
Negative Factors
Stable Revenue Base
Regis’ revenue is anchored in government funding and resident contributions, creating a predictable cash-flow foundation. That structural funding linkage and the essential nature of aged-care services support occupancy-driven revenues and downside protection versus discretionary industries.
Read all positive factors
Regis Healthcare Ltd. (REG) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$1.84B
Dividend Yield2.3%
Average Volume (3M)1.72M
Price to Earnings (P/E)39.0
Beta (1Y)1.00
Revenue Growth14.61%
EPS GrowthN/A
CountryAU
Employees11,000
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)0.10
Shares Outstanding302,361,500
10 Day Avg. Volume1,078,239
30 Day Avg. Volume1,722,836
Financial Highlights & Ratios
PEG Ratio-0.15
Price to Book (P/B)-141.20
Price to Sales (P/S)2.05
P/FCF Ratio10.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
AU$8.48Price Target Upside40.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)0.18
Revenue Forecast (FY)AU$1.39B
Regis Healthcare Ltd. Business Overview & Revenue Model
Company Description
Regis Healthcare Limited provides residential aged care services in Australia. The company offers home care services, including personal hygiene and care, dressing and undressing, mobility and transportation, rehabilitation, and others; and home h...
How the Company Makes Money
Regis Healthcare primarily makes money by operating residential aged care facilities and charging for the services provided to residents. Revenue is generally generated from (1) government funding and subsidies for eligible aged care services, whi...
Regis Healthcare Ltd. Financial Statement Overview
Summary
Income Statement
65
Positive
Balance Sheet
40
Negative
Cash Flow
55
Neutral
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.25B | 1.15B | 1.01B | 771.48M | 717.89M | 685.87M |
| Gross Profit | 139.90M | 141.46M | 47.17M | -3.78M | 5.18M | 67.54M |
| EBITDA | 169.58M | 240.44M | 191.45M | 96.81M | 55.86M | 82.65M |
| Net Income | 38.03M | 48.95M | -21.41M | -28.45M | -38.80M | 19.95M |
Balance Sheet | ||||||
| Total Assets | 2.60B | 2.11B | 1.81B | 1.71B | 1.76B | 1.75B |
| Cash, Cash Equivalents and Short-Term Investments | 197.97M | 192.47M | 64.91M | 61.32M | 4.15M | 3.89M |
| Total Debt | 7.99M | 5.11M | 3.84M | 71.07M | 113.32M | 153.41M |
| Total Liabilities | 2.63B | 2.12B | 1.84B | 1.67B | 1.68B | 1.61B |
| Stockholders Equity | -29.95M | -16.72M | -22.89M | 38.39M | 79.01M | 141.97M |
Cash Flow | ||||||
| Free Cash Flow | 233.44M | 219.64M | 186.57M | 53.73M | 67.60M | 87.75M |
| Operating Cash Flow | 389.26M | 306.11M | 252.30M | 105.16M | 114.79M | 105.03M |
| Investing Cash Flow | -320.67M | -132.74M | -136.59M | 6.58M | -48.62M | 7.50M |
| Financing Cash Flow | -50.54M | -45.81M | -112.12M | -43.17M | -62.39M | -119.47M |
Regis Healthcare Ltd. Technical Analysis
Negative
6.02
Price Trends
6.42
Negative
6.77
Negative
7.10
Negative
Market Momentum
-0.10
Positive
40.65
Neutral
20.82
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:REG, the sentiment is Negative. The current price of 6.02 is below the 20-day moving average (MA) of 6.21, below the 50-day MA of 6.42, and below the 200-day MA of 7.10, indicating a bearish trend. The MACD of -0.10 indicates Positive momentum. The RSI at 40.65 is Neutral, neither overbought nor oversold. The STOCH value of 20.82 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:REG.
Regis Healthcare Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
64 Neutral | AU$9.08B | 12.30 | 5.75% | 2.25% | 6.82% | -99.27% | |
59 Neutral | AU$380.08M | 23.92 | 16.35% | 4.60% | 6.73% | 37.16% | |
56 Neutral | AU$1.84B | 39.00 | -162.99% | 2.30% | 14.61% | ― | |
55 Neutral | AU$838.92M | 26.42 | 2.05% | 2.65% | 33.54% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$92.29M | -2.00 | -131.13% | ― | 456.50% | -457.14% |
* Healthcare Sector Average
AU:REG
Regis Healthcare Ltd.
6.02
-0.44
-6.74%
AU:RHC
Ramsay Health Care
39.65
7.65
23.92%
AU:IDX
Integral Diagnostics Ltd.
2.25
<0.01
0.13%
AU:ACL
Australian Clinical Labs Ltd
2.01
-0.84
-29.57%
AU:BOT
Botanix Pharmaceuticals Limited
0.04
-0.35
-90.91%
Regis Healthcare Ltd. Corporate Events
Regis Healthcare Cancels 125,816 Unvested Performance Rights
Mar 11, 2026
Regis Healthcare Limited has notified the market that 125,816 performance rights, classified under ASX security code REGAA, have lapsed. The lapse occurred because the conditions attached to these conditional rights were not met or could no longer...
Regis Healthcare Director Carmel Monaghan Acquires Initial Shareholding
Mar 4, 2026
Regis Healthcare has disclosed a change in director Carmel Anne Monaghan’s interests, with the director acquiring 2,200 ordinary shares in the company. The on-market purchase, completed on 25 February 2026 for a total consideration of $15,16...
Regis Healthcare lifts revenue and dividend as statutory profit halves
Feb 22, 2026
Regis Healthcare Limited reported an 18.4% increase in revenue from ordinary activities to $667.7 million for the half-year ended 31 December 2025, while statutory net profit after tax attributable to members fell 44.8% to $13.4 million. Underlyin...
Regis Healthcare Appoints Former Ramsay Executive Carmel Monaghan to Board
Jan 27, 2026
Regis Healthcare Limited has appointed experienced healthcare executive Carmel Monaghan as an independent non-executive director, effective 1 February 2026. Monaghan, former CEO of Ramsay Health Care Australia and an experienced board member in bo...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.